/LENZ
LENZ Stock - LENZ Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$18.00+5.45%
+$0.93 (+5.45%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.6
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+241.7%upside
Target: $61.51
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LENZ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$17.82 – $18.18
TARGET (TP)$61.50
STOP LOSS$16.56
RISK/REWARD1:30.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.45
52W High$50.40
52W Low$15.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $15.00M | N/A | N/A |
| Gross Profit | $-58,000 | N/A | $15.00M | $-734,000 | $-121,000 |
| Gross Margin | N/A | N/A | 100.0% | N/A | N/A |
| Operating Income | $-58,610,000 | $-72,429,000 | $-10,483,000 | $-60,443,000 | $-13,500,000 |
| Net Income | $-49,769,000 | $-69,968,000 | $-10,811,000 | $-70,760,000 | $-68,373,000 |
| Net Margin | N/A | N/A | -72.1% | N/A | N/A |
| EPS | $-2.34 | $-15.30 | $-12.89 | $-8.54 | $-8.24 |
Company Overview
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$40
Average Target
↑ 122.2% Upside
Now
$28
Low
$40
Average
$60
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 14th 2025 | Piper Sandler | Resumed | Overweight | $51← $38 |
| March 18th 2025 | TD Cowen | Initiation | Buy | $60 |
| September 27th 2024 | Raymond James | Initiation | Outperform | $37 |
| August 12th 2024 | H.C. Wainwright | Initiation | Buy | $38 |
| April 15th 2024 | William Blair | Initiation | Outperform | - |
| April 15th 2024 | Leerink Partners | Initiation | Outperform | $32 |
| April 10th 2024 | Citigroup | Initiation | Buy | $34 |
| March 27th 2024 | Piper Sandler | Initiation | Overweight | $28 |
Earnings History & Surprises
LENZBeat Rate
60%
Last 15 quarters
Avg Surprise
-30.0%
EPS vs Estimate
Beats / Misses
9/6
Last 12 quarters
Latest EPS
$-0.59
Q4 2025
EPS Surprise History
Q1 24
-207.7%
$-0.40vs$-0.13
Q2 24
-320.2%
$-3.53vs$-0.84
Q3 24
+18.4%
$-0.40vs$-0.49
Q4 24
+19.1%
$-0.38vs$-0.47
Q1 25
-9.5%
$-0.46vs$-0.42
Q2 25
+3.6%
$-0.53vs$-0.55
Q3 25
+8.6%
$-0.53vs$-0.58
Q4 25
+11.9%
$-0.59vs$-0.67
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 18, 2026 | $-0.96 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.67 | $-0.59 | +11.9% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $-0.58 | $-0.53 | +8.6% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.55 | $-0.53 | +3.6% | ✓ BEAT |
Q1 2025 | Mar 19, 2025 | $-0.42 | $-0.46 | -9.5% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.47 | $-0.38 | +19.1% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.49 | $-0.40 | +18.4% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.84 | $-3.53 | -320.2% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-0.13 | $-0.40 | -207.7% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.25 | $-0.19 | +24.0% | ✓ BEAT |
Q2 2023 | Jun 29, 2023 | $-6.79 | $-6.82 | -0.5% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-2.41 | $-3.00 | -24.5% | ✗ MISS |
Q4 2022 | Dec 30, 2022 | $-3.45 | $-3.09 | +10.5% | ✓ BEAT |
Q3 2022 | Sep 29, 2022 | $-3.11 | $-3.13 | -0.6% | ✗ MISS |
Q2 2022 | Jun 29, 2022 | $-3.44 | $-3.42 | +0.6% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | — | $-3.39 | — | — |
Q4 2021 | Dec 30, 2021 | $-2.73 | $-2.28 | +16.3% | ✓ BEAT |
Q3 2021 | Sep 29, 2021 | — | $-1.76 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-2.19 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-2.38 | — | — |
Latest News
LENZ Therapeutics Acknowledges Adverse Event Reported To FDA; Says Patient Using VIZZ Experiences Retinal Tear, Cause Uncertain Due To Pre-Existing Risk Factors
📉 NegativeBenzinga•Dec 12, 2025, 09:29 PM
LENZ plunges after adverse event report on eye therapy
📉 NegativeSeeking Alpha•Dec 12, 2025, 07:03 PM•Also:
LENZ Therapeutics And Lotus Pharmaceutical Announces That Lotus Has Submitted A New Drug Application To South Korea's Ministry Of Food And Drug Safety For Vizz, Intended To Treat Presbyopia In Adults
📈 PositiveBenzinga•Dec 1, 2025, 01:33 PM
LENZ Therapeutics shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 5, 2025, 02:26 PM
LENZ Therapeutics Q3 EPS $(0.59) Beats $(0.67) Estimate, Sales $12.500M Beat $6.828M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 01:06 PM
Raymond James Reiterates Outperform on LENZ Therapeutics, Raises Price Target to $50
📈 PositiveBenzinga•Oct 20, 2025, 05:18 PM
Piper Sandler Maintains Overweight on LENZ Therapeutics, Raises Price Target to $67
📈 PositiveBenzinga•Oct 10, 2025, 12:52 PM
LENZ Therapeutics' VIZZ Commercially Availability In U.S.
📈 PositiveBenzinga•Sep 30, 2025, 12:06 PM
LENZ Therapeutics gains on NDA submission in China for presbyopia drug LNZ100
📈 PositiveSeeking Alpha•Jul 28, 2025, 12:14 PM
Frequently Asked Questions about LENZ
What is LENZ's current stock price?
LENZ Therapeutics, Inc. (LENZ) is currently trading at $18.00 per share. The stock has moved +5.45% today.
What is the analyst price target for LENZ?
The average analyst price target for LENZ is $61.50, based on 1 analyst.
What sector is LENZ Therapeutics, Inc. in?
LENZ Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LENZ's market cap?
LENZ Therapeutics, Inc. has a market capitalization of $0.50 billion, making it a small-cap company.
Does LENZ pay dividends?
No, LENZ Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABUS
Arbutus Biopharma Corporation
$4.43
Mkt Cap: $0.9B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
GHRS
GH Research PLC
$12.96
Mkt Cap: $0.8B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
NBTX
Nanobiotix S.A.
$22.13
Mkt Cap: $1.1B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SPRY
ARS Pharmaceuticals, Inc.
$10.49
Mkt Cap: $1.0B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
Explore stocks similar to LENZ for comparison